{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T15:23:08Z","timestamp":1787412188188,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Academic Leaders Training Program of Shanghai Pudong New Area Health Commission","award":["PWRd2025-05"],"award-info":[{"award-number":["PWRd2025-05"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01556-1","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T14:37:23Z","timestamp":1787409443000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Lymph Node Ratio as a Predictive Biomarker for Individualized Benefit from Adjuvant Chemotherapy in Gastric Cancer: A Retrospective Cohort and Causal Machine Learning Study"],"prefix":"10.1007","volume":"57","author":[{"given":"Wen-qi","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-hao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3493-1247","authenticated-orcid":false,"given":"Shun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"issue":"3","key":"1556_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"18","key":"1556_CR2","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810\u201320. https:\/\/doi.org\/10.1056\/NEJMoa072252.","journal-title":"N Engl J Med"},{"issue":"33","key":"1556_CR3","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","volume":"29","author":"M Sasako","year":"2011","unstructured":"Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387\u201393. https:\/\/doi.org\/10.1200\/JCO.2011.36.5908.","journal-title":"J Clin Oncol"},{"issue":"9813","key":"1556_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","volume":"379","author":"YJ Bang","year":"2012","unstructured":"Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315\u201321. https:\/\/doi.org\/10.1016\/S0140-6736(11)61873-4.","journal-title":"Lancet"},{"issue":"12","key":"1556_CR5","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","volume":"15","author":"SH Noh","year":"2014","unstructured":"Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389\u201396. https:\/\/doi.org\/10.1016\/S1470-2045(14)70473-5.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1556_CR6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jcmgh.2017.02.003","volume":"3","author":"X Liu","year":"2017","unstructured":"Liu X, Meltzer SJ. Gastric Cancer in the Era of Precision Medicine. Cell Mol Gastroenterol Hepatol. 2017;3(3):348\u201358. https:\/\/doi.org\/10.1016\/j.jcmgh.2017.02.003.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"3","key":"1556_CR7","doi-asserted-by":"publisher","first-page":"621","DOI":"10.4143\/crt.2024.1222","volume":"57","author":"JH Yun","year":"2025","unstructured":"Yun JH, Choi YY, Cheong JH. The Current Evidence and Future Direction of Adjuvant Treatment for Gastric Cancer in the Era of Precision Medicine. Cancer Res Treat. 2025;57(3):621\u201334. https:\/\/doi.org\/10.4143\/crt.2024.1222.","journal-title":"Cancer Res Treat"},{"key":"1556_CR8","doi-asserted-by":"publisher","unstructured":"Liang Y, Liu K, Kudriashov V, et al. Comparison among Early-Onset, Late-Onset, and Conventional-Onset Adenocarcinoma of Stomach and Esophagogastric Junction: a Retrospective Study. World J Surg Onc. 2025;23(1). https:\/\/doi.org\/10.1186\/s12957-025-03867-2.","DOI":"10.1186\/s12957-025-03867-2"},{"issue":"3","key":"1556_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.4236\/jbm.2025.133021","volume":"13","author":"K Dai","year":"2025","unstructured":"Dai K, Jiang K, Huang H. Clinicopathological Characteristics and Pathogenesis of Gastric Cancer at Different Tumor Sites. J Biosci Med. 2025;13(3):271\u201383. https:\/\/doi.org\/10.4236\/jbm.2025.133021.","journal-title":"J Biosci Med"},{"key":"1556_CR10","doi-asserted-by":"publisher","first-page":"101031","DOI":"10.1016\/j.lanwpc.2024.101031","volume":"45","author":"X Gao","year":"2024","unstructured":"Gao X, Li G, Deng J, et al. Association of survival with adjuvant chemotherapy in patients with stage IB gastric cancer: a multicentre, observational, cohort study. Lancet Reg Health West Pac. 2024;45:101031. https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101031.","journal-title":"Lancet Reg Health West Pac"},{"issue":"2","key":"1556_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/00365521.2020.1716062","volume":"55","author":"Y Wang","year":"2020","unstructured":"Wang Y, Guo S, Zhang J, Meng X, yu, Zheng Z, chao, Zhao Y. A SEER population analysis of stage IB resected gastric cancer: who can benefit from adjuvant therapy? Scand J Gastroenterol. 2020;55(2):193\u2013201. https:\/\/doi.org\/10.1080\/00365521.2020.1716062.","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"1556_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-020-01042-y","volume":"24","author":"Japanese Gastric Cancer Association","year":"2021","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24(1):1\u201321. https:\/\/doi.org\/10.1007\/s10120-020-01042-y.","journal-title":"Gastric Cancer"},{"key":"1556_CR13","doi-asserted-by":"publisher","unstructured":"Korean Practice Guideline for Gastric Cancer. 2018: an Evidence-based, Multi-disciplinary Approach. J Gastric Cancer. 2019;19(1):1\u201348. https:\/\/doi.org\/10.5230\/jgc.2019.19.e8","DOI":"10.5230\/jgc.2019.19.e8"},{"key":"1556_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40880-019-0349-9","volume":"39","author":"FH Wang","year":"2019","unstructured":"Wang FH, Shen L, Li J, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun (Lond). 2019;39:10. https:\/\/doi.org\/10.1186\/s40880-019-0349-9.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"1556_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/01.sla.0000149300.28588.23","volume":"241","author":"BJ Dicken","year":"2005","unstructured":"Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241(1):27\u201339. https:\/\/doi.org\/10.1097\/01.sla.0000149300.28588.23.","journal-title":"Ann Surg"},{"issue":"8","key":"1556_CR16","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s00432-019-02963-7","volume":"145","author":"JE Hwang","year":"2019","unstructured":"Hwang JE, Kim H, Shim HJ, et al. Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer. J Cancer Res Clin Oncol. 2019;145(8):2157\u201366. https:\/\/doi.org\/10.1007\/s00432-019-02963-7.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"1556_CR17","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.ejso.2016.03.001","volume":"42","author":"K Yamashita","year":"2016","unstructured":"Yamashita K, Hosoda K, Ema A, Watanabe M. Lymph node ratio as a novel and simple prognostic factor in advanced gastric cancer. Eur J Surg Oncol. 2016;42(9):1253\u201360. https:\/\/doi.org\/10.1016\/j.ejso.2016.03.001.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"1556_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10120-013-0253-y","volume":"17","author":"A Ema","year":"2014","unstructured":"Ema A, Yamashita K, Sakuramoto S, et al. Lymph node ratio is a critical prognostic predictor in gastric cancer treated with S-1 chemotherapy. Gastric Cancer. 2014;17(1):67\u201375. https:\/\/doi.org\/10.1007\/s10120-013-0253-y.","journal-title":"Gastric Cancer"},{"issue":"8","key":"1556_CR19","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/BF02574500","volume":"9","author":"E Bando","year":"2002","unstructured":"Bando E, Yonemura Y, Taniguchi K, Fushida S, Fujimura T, Miwa K. Outcome of ratio of lymph node metastasis in gastric carcinoma. Ann Surg Oncol. 2002;9(8):775\u201384. https:\/\/doi.org\/10.1007\/BF02574500.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1556_CR20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1245\/s10434-008-0240-4","volume":"16","author":"Dzhi Xu","year":"2009","unstructured":"Xu Dzhi, Geng Q, rong, Long Z, jie, et al. Positive lymph node ratio is an independent prognostic factor in gastric cancer after d2 resection regardless of the examined number of lymph nodes. Ann Surg Oncol. 2009;16(2):319\u201326. https:\/\/doi.org\/10.1245\/s10434-008-0240-4.","journal-title":"Ann Surg Oncol"},{"issue":"44","key":"1556_CR21","doi-asserted-by":"publisher","first-page":"e13079","DOI":"10.1097\/MD.0000000000013079","volume":"97","author":"M Hu","year":"2018","unstructured":"Hu M, Zhang S, Yang X, et al. The prognostic value of lymph node ratio for local advanced gastric cancer patients with adjuvant chemoradiotherapy after D2 gastrectomy. Med (Baltim). 2018;97(44):e13079. https:\/\/doi.org\/10.1097\/MD.0000000000013079.","journal-title":"Med (Baltim)"},{"issue":"2","key":"1556_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.5230\/jgc.2016.16.2.105","volume":"16","author":"Y Kim","year":"2016","unstructured":"Kim Y, Park SH, Kim KM, et al. The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial. J Gastric Cancer. 2016;16(2):105\u201310. https:\/\/doi.org\/10.5230\/jgc.2016.16.2.105.","journal-title":"J Gastric Cancer"},{"issue":"4","key":"1556_CR23","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/01.sla.0000250423.43436.e1","volume":"245","author":"A Marchet","year":"2007","unstructured":"Marchet A, Mocellin S, Ambrosi A, et al. The Ratio Between Metastatic and Examined Lymph Nodes (N Ratio) Is an Independent Prognostic Factor in Gastric Cancer Regardless of the Type of Lymphadenectomy. Ann Surg. 2007;245(4):543\u201352. https:\/\/doi.org\/10.1097\/01.sla.0000250423.43436.e1.","journal-title":"Ann Surg"},{"issue":"1","key":"1556_CR24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/cam4.311","volume":"4","author":"A Ema","year":"2015","unstructured":"Ema A, Waraya M, Yamashita K, et al. Identification of EGFR expression status association with metastatic lymph node density (ND) by expression microarray analysis of advanced gastric cancer. Cancer Med. 2015;4(1):90\u2013100. https:\/\/doi.org\/10.1002\/cam4.311.","journal-title":"Cancer Med"},{"key":"1556_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1515\/med-2020-0023","volume":"15","author":"L Yu","year":"2020","unstructured":"Yu L, Zhang XT, Guan SH, Cheng YF, Li LX. The Number of Negative Lymph Nodes is Positively Associated with Survival in Esophageal Squamous Cell Carcinoma Patients in China. Open Med (Wars). 2020;15:152\u20139. https:\/\/doi.org\/10.1515\/med-2020-0023.","journal-title":"Open Med (Wars)"},{"issue":"1","key":"1556_CR26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1146\/annurev-biodatasci-103123-095750","volume":"8","author":"J Ab\u00e9cassis","year":"2025","unstructured":"Ab\u00e9cassis J, Dumas \u00c9, Alberge J, Varoquaux G. From Prediction to Prescription: Machine Learning and Causal Inference for the Heterogeneous Treatment Effect. Annu Rev Biomed Data Sci. 2025;8(1):381\u2013404. https:\/\/doi.org\/10.1146\/annurev-biodatasci-103123-095750.","journal-title":"Annu Rev Biomed Data Sci"},{"issue":"4","key":"1556_CR27","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/s41591-024-02902-1","volume":"30","author":"S Feuerriegel","year":"2024","unstructured":"Feuerriegel S, Frauen D, Melnychuk V, et al. Causal machine learning for predicting treatment outcomes. Nat Med. 2024;30(4):958\u201368. https:\/\/doi.org\/10.1038\/s41591-024-02902-1.","journal-title":"Nat Med"},{"issue":"23","key":"1556_CR28","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1002\/sim.7820","volume":"37","author":"T Wendling","year":"2018","unstructured":"Wendling T, Jung K, Callahan A, Schuler A, Shah NH, Gallego B. Comparing methods for estimation of heterogeneous treatment effects using observational data from health care databases. Stat Med. 2018;37(23):3309\u201324. https:\/\/doi.org\/10.1002\/sim.7820.","journal-title":"Stat Med"},{"key":"1556_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.psychres.2019.03.001","volume":"275","author":"KK Mak","year":"2019","unstructured":"Mak KK, Lee K, Park C. Applications of machine learning in addiction studies: A systematic review. Psychiatry Res. 2019;275:53\u201360. https:\/\/doi.org\/10.1016\/j.psychres.2019.03.001.","journal-title":"Psychiatry Res"},{"key":"1556_CR30","unstructured":"Smartphones dependency risk analysis using machine-learning predictive models | Scientific Reports. Accessed September 9. 2025. https:\/\/www.nature.com\/articles\/s41598-022-26336-2"},{"key":"1556_CR31","doi-asserted-by":"publisher","unstructured":"A unified approach to interpreting model predictions | Proceedings of the 31st International Conference on Neural Information Processing Systems. Accessed September 9. 2025. https:\/\/doi.org\/10.5555\/3295222.3295230","DOI":"10.5555\/3295222.3295230"},{"key":"1556_CR32","doi-asserted-by":"publisher","unstructured":"Hong W, qi, Hu R, hao, Jiang X hua, Zhang S. Time-Varying Prognosis and Competing Mortality in Gastric Cancer Survivors: Implications for Age-Stratified Surveillance Strategies. Journal of Gastrointestinal Surgery. Published online February 24, 2026:102382. https:\/\/doi.org\/10.1016\/j.gassur.2026.102382","DOI":"10.1016\/j.gassur.2026.102382"},{"issue":"18","key":"1556_CR33","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1097\/CM9.0000000000003259","volume":"137","author":"X Wang","year":"2024","unstructured":"Wang X, Gao X, Yu J, Zhang X, Nie Y. Emerging trends in early-onset gastric cancer. Chin Med J (Engl). 2024;137(18):2146\u201356. https:\/\/doi.org\/10.1097\/CM9.0000000000003259.","journal-title":"Chin Med J (Engl)"},{"issue":"21","key":"1556_CR34","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.3390\/cancers14215417","volume":"14","author":"FL Ning","year":"2022","unstructured":"Ning FL, Zhang NN, Zhao ZM, et al. Global, Regional, and National Burdens with Temporal Trends of Early-, Intermediate-, and Later-Onset Gastric Cancer from 1990 to 2019 and Predictions up to 2035. Cancers. 2022;14(21):5417. https:\/\/doi.org\/10.3390\/cancers14215417.","journal-title":"Cancers"},{"issue":"1","key":"1556_CR35","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.1038\/s41467-022-33282-0","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, Xu C, Wang B, et al. Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies. Nat Commun. 2022;13(1):5723. https:\/\/doi.org\/10.1038\/s41467-022-33282-0.","journal-title":"Nat Commun"},{"issue":"1","key":"1556_CR36","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/cncr.26248","volume":"118","author":"KE Hoffman","year":"2012","unstructured":"Hoffman KE, Neville BA, Mamon H, et al. Adjuvant therapy for elderly patients with resected gastric adenocarcinoma: population-based practices and treatment effectiveness. Cancer. 2012;118(1):248\u201357. https:\/\/doi.org\/10.1002\/cncr.26248.","journal-title":"Cancer"},{"issue":"39","key":"1556_CR37","doi-asserted-by":"publisher","first-page":"6568","DOI":"10.3748\/wjg.v19.i39.6568","volume":"19","author":"YX Liang","year":"2013","unstructured":"Liang YX, Deng JY, Guo HH, et al. Characteristics and prognosis of gastric cancer in patients aged\u2009\u2265\u200970 years. World J Gastroenterol. 2013;19(39):6568\u201378. https:\/\/doi.org\/10.3748\/wjg.v19.i39.6568.","journal-title":"World J Gastroenterol"},{"issue":"12","key":"1556_CR38","first-page":"1248","volume":"18","author":"W Wang","year":"2015","unstructured":"Wang W, Xue Y, Zhuo C, Li S, Li Z, Cheng L. [Analysis of clinicopathological features and prognosis in patients with advanced gastric cancer in different locations]. Zhonghua Wei Chang Wai Ke Za Zhi. 2015;18(12):1248\u201352.","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"issue":"7","key":"1556_CR39","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.ejso.2017.03.013","volume":"43","author":"K Bouliaris","year":"2017","unstructured":"Bouliaris K, Rachiotis G, Diamantis A, Christodoulidis G, Polychronopoulou E, Tepetes K. Lymph node ratio as a prognostic factor in gastric cancer patients following D1 resection. Comparison with the current TNM staging system. Eur J Surg Oncol. 2017;43(7):1350\u20136. https:\/\/doi.org\/10.1016\/j.ejso.2017.03.013.","journal-title":"Eur J Surg Oncol"},{"key":"1556_CR40","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12893-023-02127-y","volume":"23","author":"M Ergen\u00e7","year":"2023","unstructured":"Ergen\u00e7 M, Uprak TK, Ak\u0131n M\u0130, Hekimo\u011flu EE, \u00c7elikel \u00c7A, Ye\u011fen C. Prognostic significance of metastatic lymph node ratio in gastric cancer: a Western-center analysis. BMC Surg. 2023;23:220. https:\/\/doi.org\/10.1186\/s12893-023-02127-y.","journal-title":"BMC Surg"},{"issue":"2","key":"1556_CR41","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.suronc.2015.03.001","volume":"24","author":"OC Kutlu","year":"2015","unstructured":"Kutlu OC, Watchell M, Dissanaike S. Metastatic lymph node ratio successfully predicts prognosis in western gastric cancer patients. Surg Oncol. 2015;24(2):84\u20138. https:\/\/doi.org\/10.1016\/j.suronc.2015.03.001.","journal-title":"Surg Oncol"},{"key":"1556_CR42","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ijsu.2018.08.002","volume":"57","author":"J Zhu","year":"2018","unstructured":"Zhu J, Xue Z, Zhang S, et al. Integrated analysis of the prognostic role of the lymph node ratio in node-positive gastric cancer: A meta-analysis. Int J Surg. 2018;57:76\u201383. https:\/\/doi.org\/10.1016\/j.ijsu.2018.08.002.","journal-title":"Int J Surg"},{"issue":"2","key":"1556_CR43","doi-asserted-by":"publisher","first-page":"994","DOI":"10.21873\/invivo.12792","volume":"36","author":"T AOYAMA","year":"2022","unstructured":"AOYAMA T, KOMORI K, TAMAGAWA A, et al. Clinical Influence of the Lymph Node Ratio on Lymph Node Metastasis-positive Gastric Cancer Patients Who Receive Curative Treatment. Vivo. 2022;36(2):994\u20131000. https:\/\/doi.org\/10.21873\/invivo.12792.","journal-title":"Vivo"},{"issue":"6","key":"1556_CR44","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.4240\/wjgs.v16.i6.1660","volume":"16","author":"SF Nie","year":"2024","unstructured":"Nie SF, Wang CY, Li L, Yang C, Zhu ZM, Fei JD. Tumor recurrence and survival prognosis in patients with advanced gastric cancer after radical resection with radiotherapy and chemotherapy. World J Gastrointest Surg. 2024;16(6):1660\u20139. https:\/\/doi.org\/10.4240\/wjgs.v16.i6.1660.","journal-title":"World J Gastrointest Surg"},{"issue":"12","key":"1556_CR45","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1007\/s00268-020-05739-0","volume":"44","author":"S Nakamura","year":"2020","unstructured":"Nakamura S, Kanda M, Ito S, et al. Accurate Risk Stratification of Patients with Node-Positive Gastric Cancer by Lymph Node Ratio. World J Surg. 2020;44(12):4184\u201392. https:\/\/doi.org\/10.1007\/s00268-020-05739-0.","journal-title":"World J Surg"},{"issue":"11","key":"1556_CR46","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1245\/s10434-020-08616-1","volume":"27","author":"K Kano","year":"2020","unstructured":"Kano K, Yamada T, Yamamoto K, et al. Association Between Lymph Node Ratio and Survival in Patients with Pathological Stage II\/III Gastric Cancer. Ann Surg Oncol. 2020;27(11):4235\u201347. https:\/\/doi.org\/10.1245\/s10434-020-08616-1.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"1556_CR47","doi-asserted-by":"publisher","first-page":"e9703","DOI":"10.1097\/MD.0000000000009703","volume":"97","author":"SA Hong","year":"2018","unstructured":"Hong SA, Son MW, Cho J, et al. Prognostic value of fibrosis ratio in metastatic lymph nodes of node-positive advanced gastric cancer. Med (Baltim). 2018;97(3):e9703. https:\/\/doi.org\/10.1097\/MD.0000000000009703.","journal-title":"Med (Baltim)"},{"issue":"3","key":"1556_CR48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4174\/astr.2017.92.3.117","volume":"92","author":"YW Chang","year":"2017","unstructured":"Chang YW, Kim HS, Jung SP, et al. Significance of micrometastases in the calculation of the lymph node ratio for papillary thyroid cancer. Ann Surg Treat Res. 2017;92(3):117\u201322. https:\/\/doi.org\/10.4174\/astr.2017.92.3.117.","journal-title":"Ann Surg Treat Res"},{"issue":"1","key":"1556_CR49","doi-asserted-by":"publisher","first-page":"5220","DOI":"10.1038\/s41467-026-71347-6","volume":"17","author":"P Ding","year":"2026","unstructured":"Ding P, Chen S, Guo H, Yang S, Wang X, Han X, Yang J, Wu H, Wu J, Tian Y, Ma W, Li X, Guo Z, Gu R, Zhang L, Meng N, Liu Y, Meng L, Zhao Q. A deep learning-based digital biopsy for predicting early recurrence in gastric cancer. Nat Commun. 2026;17(1):5220. https:\/\/doi.org\/10.1038\/s41467-026-71347-6.","journal-title":"Nat Commun"},{"issue":"15","key":"1556_CR50","doi-asserted-by":"publisher","first-page":"e2411490","DOI":"10.1002\/advs.202411490","volume":"12","author":"P Ding","year":"2025","unstructured":"Ding P, Yang J, Guo H, Wu J, Wu H, Li T, Gu R, Zhang L, He J, Yang P, Tian Y, Meng N, Li X, Guo Z, Meng L, Zhao Q. Multimodal Artificial Intelligence-Based Virtual Biopsy for Diagnosing Abdominal Lavage Cytology-Positive Gastric Cancer. Adv Sci (Weinh). 2025;12(15):e2411490. https:\/\/doi.org\/10.1002\/advs.202411490 . Epub 2025 Feb 22.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"1556_CR51","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41746-025-02268-9","volume":"9","author":"S Chen","year":"2026","unstructured":"Chen S, Ding P, Yang Y, Ma S, Guo H, Han X, Yang J, Ma W, Meng N, Xia Z, Li X, Zhang L, Shi Y, Guo Z, Gao K, Gu R, Long H, Meng L, Zhao Q. Multimodal digital biopsy for preoperative prediction of occult peritoneal metastasis in gastric cancer. NPJ Digit Med. 2026;9(1):107. https:\/\/doi.org\/10.1038\/s41746-025-02268-9.","journal-title":"NPJ Digit Med"},{"issue":"1","key":"1556_CR52","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1186\/s12916-025-04393-4","volume":"23","author":"P Ding","year":"2025","unstructured":"Ding P, Chen S, Guo H, Yang J, Fu Q, Wang B, Gu R, Zhang L, Wu J, Wu H, Meng N, Li X, Guo Z, Tian Y, Meng L, Zhao Q. Radiomics-based ensemble model predicts postoperative recurrence of gastric cancer. BMC Med. 2025;23(1):656. https:\/\/doi.org\/10.1186\/s12916-025-04393-4.","journal-title":"BMC Med"},{"issue":"43","key":"1556_CR53","doi-asserted-by":"publisher","first-page":"e08190","DOI":"10.1002\/advs.202508190","volume":"12","author":"P Ding","year":"2025","unstructured":"Ding P, Yang J, Chen S, Guo H, Wu J, Wu H, Yang L, Ma W, Tian Y, Gu R, Zhang L, Meng N, Li X, Guo Z, Liu Y, Meng L, Zhao Q. Interpretable Multimodal Fusion Model Enhances Postoperative Recurrence Prediction in Gastric Cancer. Adv Sci (Weinh). 2025;12(43):e08190. https:\/\/doi.org\/10.1002\/advs.202508190.","journal-title":"Adv Sci (Weinh)"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01556-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01556-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01556-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T14:37:24Z","timestamp":1787409444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01556-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1556"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01556-1","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"24 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of Shanghai East Hospital. Informed consent was waived due to the retrospective nature of the study and the use of de-identified patient data.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"197"}}